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Genetic variants of folate and methionine metabolism and
PCNSL incidence in a German patient population
Abstract
Functional genetic polymorphisms involved in folate and methionine metabolism play an important role
in both DNA synthesis and methylation, and affect the risk of various malignancies including
lymphoproliferative disorders such as systemic non-Hodgkin's lymphoma. In a retrospective analysis of
185 immunocompetent patients with primary central nervous system lymphoma (PCNSL) and 212
population controls we therefore investigated eight genetic polymorphisms affecting methionine
metabolism for potential association with the development of PCNSL. We observed underrepresentation
of the G-allele of the methyltetrahydrofolate homocysteine S-methyltransferase (MTR) c.2756A > G
(D919G) missense polymorphism among PCNSL patients (P = 0.045; odds ratio (OR) = 0.65;
0.43-0.99). Furthermore, for the methylenetetrahydrofolate reductase (MTHFR) c.1298A > C (E429A)
polymorphism the mutated C-allele was found more frequently among PCNSL patients than among
population controls (P = 0.026; OR = 1.57; 1.05-2.34). There were no associations of the other
polymorphisms investigated (MTHFR c.677C > T, transcobalamin 2 (Tc2) c.776C > G, cystathionin
beta-synthase (CBS) c.844_855ins68, reduced folate carrier-1 (RFC-1) c.80G > A, thymidylate synthase
(TYMS) 28-bp repeat, and dihydrofolate reductase (DHFR) c.594 + 59del19 bp) and the presence of
PCNSL. This analysis is the largest to date to evaluate associations between genetic variants of folate
and methionine metabolism and PCNSL. Our results suggest the hypothesis that folate and methionine
metabolism is relevant to susceptibility to PCNSL.
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Abstract 
Functional genetic polymorphisms involved in folate and methionine metabolism play an 
important role in both DNA synthesis and methylation, and affect the risk of various 
malignancies including lymphoproliferative disorders such as systemic non-Hodgkin’s 
lymphoma. In a retrospective analysis of 185 immunocompetent patients with primary central 
nervous system lymphoma (PCNSL) and 212 population controls we therefore investigated 
eight genetic polymorphisms influencing methionine metabolism for a potential association 
with the development of PCNSL.  
We observed an underrepresentation of the G-allele of the methyltetrahydrofolate 
homocysteine S-methyltransferase (MTR) c.2756A>G (D919G) missense polymorphism 
among PCNSL patients (p=0.045; odds ratio [OR]=0.65; 0.43-0.99). Furthermore, for the 
methylenetetrahydrofolate reductase (MTHFR) c.1298A>C (E429A) polymorphism the 
mutated C-allele was found more frequently among PCNSL patients in comparison to 
population controls (p=0.026; OR=1.57; 1.05-2.34). There were no associations of the other 
polymorphisms investigated [MTHFR c.677C>T, transcobalamin 2 (Tc2) c.776C>G, 
cystathionin beta-synthase (CBS) c.844_855ins68, reduced folate carrier-1 (RFC-1) c.80G>A, 
thymidylate synthase (TYMS) 28-bp repeat, and dihydrofolate reductase (DHFR) 
c.594+59del19bp] and the presence of PCNSL.  
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The present analysis is the largest to date to evaluate associations between genetic variants of 
folate and methionine metabolism and PCNSL. Our results suggest the hypothesis that folate 
and methionine metabolism is relevant for the susceptibility to PCNSL. 
 
Keywords: Genetic polymorphism - Folate - Methionine - DNA methylation - PCNSL 
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Introduction 
Primary central nervous system lymphoma (PCNSL) is an aggressive subtype of non-
Hodgkin’s lymphoma (NHL) arising within the central nervous system (CNS). The vast 
majority are diffuse large B-cell lymphomas (DLBCL) derived from germinal center B cells 
[1], and pathogenic factors are largely unclear, so far. In a recent retrospective analysis no 
association between PCNSL and human leukocyte antigens (HLA) was found [2]. PCNSL 
characteristically reveals genetic instability with chromosomal imbalances [3]. Thus, 
metabolic factors and conditions contributing to the maintenance of DNA integrity may be 
influential for the development and growth of PCNSL cells via altered DNA synthesis and 
methylation of oncogenes and tumor suppressor genes. Aberrant folate and methionine 
metabolism could interfere with both processes. Genetic variants that functionally influence 
enzymes, transporter proteins or receptor proteins involved in folate and methionine 
metabolism are associated with different types of extracranial human cancer, such as systemic 
NHL, acute leukemia, and colorectal cancer [4-8].  
 
In immunocompetent patients, an association of PCNSL with the methyltetrahydrofolate 
homocysteine S-methyltransferase (MTR) c.2756A>G variant has been reported [9], and this 
polymorphism has also been described to alter susceptibility to other intracranial tumors 
including glioblastoma and anaplastic meningioma [10, 11].    
 
In the present explorative study we aimed to analyze the frequency of eight functional genetic 
variants of folate and methionine metabolism in a collective of 185 patients with PCNSL 
compared with 212 healthy controls, making this study the largest to date to evaluate this 
association. 
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Materials and methods 
Study population 
We investigated 185 consecutive immunocompetent PCNSL patients of Caucasian origin 
recruited for the German multicenter phase IV trial (G-PCNSL-SG-1) between 08/2000 and 
12/2004 (43.8% female; median age at diagnosis 60.4 years, range 18-81 years). The aim of 
the G-PCNSL-SG-1 study is to analyze the value of whole brain radiotherapy after 6 courses 
of high-dose methotrexate (MTX) in newly diagnosed PCNSL. Inclusion criteria for the G-
PCNSL-SG-1 study were a newly diagnosed and histologically or cytologically (in the 
cerebrospinal fluid) confirmed PCNSL in an immunocompetent patient and adequate renal 
and bone marrow function. Exclusion criteria were systemic manifestation of NHL and 
additional malignancies as well as immunodeficiency or concomitant immunosuppressive 
therapy. 212 apparently healthy Caucasian Bonn area residents (45.8% female; median age 
63.0 years, range 39-85 years) without a history of cancer, recruited as control population for 
an ongoing study on atherosclerosis, served as controls [12, 13]. The same collective had 
already been used as control group for a small case-control study analyzing folate-
metabolizing pathway polymorphisms in patients with PCNSL [9]. Characteristics of the 
study population have also been summarized in Table 1.  
The study was approved by the respective local ethics committees, and all participants gave 
written informed consent.  
 
DNA extraction and genotyping 
Blood samples were collected prospectively upon enrollment onto the G-PCNSL-SG-1 trial 
before treatment was started. Genomic DNA was extracted from mononuclear cells using the 
QIAamp® DNA Blood Mini Kit (Qiagen, Hilden, Germany). Genotyping of eight 
polymorphisms [methylenetetrahydrofolate reductase (MTHFR) c.677C>T (A222V), MTHFR 
c.1298A>C (E429A), MTR c.2756A>G (D919G), transcobalamin 2 (Tc2) c.776C>G (P259R), 
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cystathionin beta-synthase (CBS) c.844_855ins68 (change of transcript levels), reduced folate 
carrier-1 (RFC-1) c.G80A (R27H), thymidylate synthase (TYMS) 28bp rep (2R>3R), 
dihydrofolate reductase (DHFR) c.594+59del19bp (change of transcript levels)] was 
performed by amplification of genomic DNA applying polymerase chain reaction (PCR) and 
subsequent restriction enzyme digestion or by allele specific PCR, followed by agarose gel 
electrophoresis [14-20]. 
 
Statistical analysis 
The distribution of age and gender in the patient and the control collective was compared 
applying t-test for two independent samples and Pearson`s Chi2 test, respectively. For the 
tested genotypes the Hardy-Weinberg equation was calculated for all PCNSL patients and 
controls together with a Chi2 goodness-of-fit test (df=2). The two-sided Pearson`s Chi2 test 
was used to analyze the distribution of the respective genotypes in the patient and the control 
group for statistical significance. Threshold was defined with alpha <0.05. Due to the low 
frequencies of the MTR c.2756GG and the MTHFR c.1298CC homozygous variants, we 
additionally evaluated the presence of at least one mutant allele (AG/GG or AC/CC) versus 
homozygosity for the wildtype allele (AA) in the patient and the control sample (Pearson`s 
Chi2 test; df=1). All analyses were purely explorative, so that correction for multiple testing 
was not regarded necessary, and all findings require reevaluation in future studies. 
Odds ratios (OR) together with 95% confidence intervals (CI) were calculated for the 
combined MTR c.2756AG/GG and MTHFR c.1298AC/CC genotypes, respectively.  
Furthermore, multinominal regression analysis with alpha=0.05 was applied to test the 
independent association of the respective polymorphisms with PCNSL and to exclude 
confounding effects of age, gender, or multiple testing.  
All statistical calculations were performed using the Statistical Package for the Social 
Sciences (SPSS) software version 16.0 (SPSS, Chicago, IL, USA). 
  
 
7
Results  
There were no significant differences concerning age and gender between the patient and the 
control cohort. Genotype distributions in all PCNSL patients and controls are shown in Table 
2. The distribution of allelotypes of the polymorphisms did not significantly deviate from the 
Hardy-Weinberg equilibrium (data not shown). Allelic frequencies of the MTHFR c.677C>T, 
MTHFR c.1298A>C, MTR c.2756A>G, Tc2 c.776C>G, CBS c.844_855ins68, RFC-1 
c.80G>A, TYMS 28-bp repeat, and the DHFR c.594+59del19bp polymorphism in the control 
group are similar to those found in another independent healthy German population [21] and 
those reported for other Caucasian populations [15, 16, 22]. 
 
The MTR c.2756A>G polymorphism (G-allele) was less frequent in PCNSL patients than in 
controls (patients AA/AG/GG: 71.3/24.9/3.8 and controls AA/AG/GG: 61.8/34.0/4.2; 
Chi2=4,17 (Pearson), p=0.125 for trend, df=2). In Pearson`s Chi2 test of the pooled genotypes 
MTR c.2756AA versus AG/GG without correction for multiple testing, the MTR c.2756G 
allele was significantly underrepresented in the patient sample; at least one mutant allele (the 
MTR c.2756AG and GG genotypes) was detected in 28.7% of PCNSL patients compared to 
38.2% of controls (Chi2=4.04, p=0.045, df=1; Table 3). Overall, multinominal logistic 
regression analysis with simultaneous analysis of all eight polymorphisms together with age 
and gender as co-variables reproduced the above findings (Chi2=4.449, p=0.035 for pooled 
genotypes, df=1). 
 
Furthermore, for the MTHFR c.1298A>C polymorphism, the mutated C-allele was observed 
more frequently among PCNSL patients than in controls (patients AA/AC/CC: 38.8/52.1/9.1 
and controls AA/AC/CC: 50.5/42.0/7.5; Chi2=5.38 (Pearson), p=0.068 for trend, df=2). This 
trend was significant in the uncorrected explorative analysis (MTHFR c.1298AA versus AC 
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and CC genotypes: Chi2=5.00, p=0.026, df=1; Table 3) as well as in multinomial logistic 
regression analysis of the pooled genotypes (Chi2=5.179, p=0.023). 
 
A reduced risk estimate was found for the MTR c.2756AG/GG genotype when MTR 
c.2756AA was the referent group (OR=0.65; 0.43-0.99; Table 3), whereas a small increased 
risk estimate for PCNSL was associated with the MTHFR c.1298AC/CC genotype versus 
homozygosity for the wildtype allele AA (OR=1.57; 1.05-2.34; Table 3). 
 
There were no significant associations of the other polymorphisms investigated (MTHFR 
c.677C>T, Tc2 c.776C>G, CBS c.844_855ins68, RFC-1 c.80G>A, TYMS 28-bp repeat, and 
DHFR c.594+59del19bp; Table 2) and the development of PCNSL.  
 
 
Discussion 
The findings presented here suggest an association between the MTR c.2756A>G (D919G) as 
well as the MTHFR c.1298A>C (E429A) polymorphisms and the presence of PCNSL, with 
the MTR c.2756G allele being less frequent, and the mutated MTHFR c.1298C allele more 
common in patients than in population controls.  
As for the MTR c.2756A>G polymorphism these data confirm the results of a previous case-
control study on 31 German PCNSL patients which found significantly fewer carriers of the 
MTR c.2756A>G missense polymorphism among the patients [9]. Of note, control samples of 
both studies overlap, so the observed effect could have been due to a coincidental 
overrepresentation of the G-allele in the control group. However, this seems unlikely, as 
allelic frequencies of the MTR c.2756A>G polymorphism in this control group are similar to 
those of another independent healthy German population [21]. Interestingly, in this population 
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sample the presence of the MTR c.2756G allele has been correlated with disease-free 
longevity. MTR catalyzes the remethylation of homocysteine to methionine. The G-allele of 
MTR c.2756A>G has been suggested to lead to a higher MTR activity, supposedly changing 
the kinetics of nucleic acid and S-adenosylmethionine (SAM) synthesis. SAM is necessary for 
DNA methylation. Thus, the MTR variant may influence both DNA synthesis and 
methylation, whereas any concrete influence of the variant on tumorigenesis remains 
speculative. Our results showing a reduced frequency of the MTR c.2756G allele in patients 
with PCNSL are in line with previous studies on the MTR missense dimorphism c.2756A>G 
which found a lower frequency in patients with colorectal cancer [7], cervical intraepithelial 
neoplasia [23] and follicular NHL [8], and (among primary brain tumors) with GBM and 
anaplastic meningioma [10, 11].  
 
The second genetic variant in this study, MTHFR c.1298A>C, with a significant positive 
association with PCNSL in explorative data analysis has previously been reported to be 
associated with some types of human cancer [4-6, 24]. MTHFR catalyzes the conversion of 
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which acts as a methyl donor for 
the transformation of homocysteine to methionine. Both polymorphisms in the MTHFR gene, 
c.677C>T and c.1298A>C, lead to reduced enzyme activity. While these variants were both 
observed more frequently in our patient group, this effect did not reach statistical significance 
for the MTHFR c.677C>T polymorphism. That could be due to a too small sample size and 
should be reevaluated in further patient collectives, although PCNSL is a rare disease, and 
large patient cohorts are difficult to obtain. Possible mechanisms underlying an association of 
the MTHFR variants include effects on folate derivatization, on homocysteine remethylation 
to methionine and on SAM availability for DNA synthesis. More basic research is necessary 
to elucidate such putative interactions.     
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However, as pointed out, the reported variants do not exclusively affect pathways in PCNSL 
development but are apparently relevant for tumorigenesis in general. Moreover, due to the 
case-control design of our study, and due to the "matching procedure" we employed (which 
was not done between individual cases and controls, but between the entire group of cases and 
the entire group of controls) certain caveats are necessary, including the possibility of 
unrecognized selection bias and unknown confounders which cannot be fully controlled 
for. As a result, a definitive relationship between "exposure" (i.e. MTR and MTHFR 
polymorphisms) and PCNSL has not been established. This study is an explorative, 
hypothesis-generating investigation. Our results require replication in additional large trials 
and in pooled analyses. 
 
In summary, the present analysis is the largest to date to evaluate associations between 
polymorphisms in folate-metabolizing genes and PCNSL, and suggests that certain functional 
genetic variants of folate and methionine metabolism alter susceptibility to PCNSL. 
Specifically, the MTR c.2756G allele may reduce susceptibility (a protective effect) while the 
MTHFR c.1298C allele may increase susceptibility. Since folate and methionine metabolism 
is closely associated with the availability of methionine, folate and vitamin B12, it might even 
be possible that nutritional factors modify the incidence of PCNSL, as has been described for 
other tumors. 
 
Folate and methionine metabolism also seems to affect anticancer therapy with MTX which is 
still the most efficient chemotherapy component in the treatment of PCNSL and directly 
interferes with methionine metabolism. Therefore, further studies on the impact of folate and 
methionine metabolism on incidence and treatment outcome of PCNSL are warranted. 
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Table 1 Characteristics of patients with primary central nervous system lymphoma  
(PCNSL) and control individuals 
 
 
 
PCNSL 
 
Controls 
 
Characteristics 
 
No. (%) Median (Range)
 
No. (%) Median (Range) 
 
No. of individuals 185 - 212 - 
 
Demographic data     
     Male 104 (56.2) - 115 (54.2) - 
     Female 81 (43.8) - 97 (45.8) - 
     Age at diagnosis [years] - 60.4 (18-81) - 63.0 (39-85) 
     Descent Caucasian Caucasian 
 
Prior therapy None - 
 
Table 3 Pearson`s Chi2 analysis, odds ratios (OR), and 95% confidence intervals (CI) of  
the pooled genotypes MTR c.2756AG/GG vs. AA and MTHFR c.1298AC/CC vs. AA in 
PCNSL patients and controls  
 
Genotype PCNSL (n = 185) Controls (n = 212) 
  
 
 
MTR c.2756A>G  
  
χ2 (df = 1) P (χ2) OR (95% CI) 
 
       AA 0.71 0.62 
 
       AG or GG 0.29 0.38 
4.04 0.045 0.65 (0.43-0.99) 
 
MTHFR c.1298A>C 
  
χ2  P  OR (95% CI) 
 
       AA 0.39 0.50 
 
       AC or CC 
 
0.61 0.50 
5.00 0.026 1.57 (1.05-2.34) 
 
The distribution of the different genotypes among PCNSL patients and controls is given  
as relative amount.  
Table 2 Distribution of polymorphisms involved in folate-metabolizing 
pathway genes in patients with primary central nervous system lymphoma  
(PCNSL) and controls: Pearson`s Chi2 analysis 
 
MTHFR c.677C>T CC CT TT χ2 (df = 2) P (χ2) 
 
PCNSL (n = 185) 
 
0.42 
 
0.44 
 
0.14 
 
2.12 
 
0.346 
 
Controls (n = 212) 
 
0.45 
 
0.45 0.09   
 
MTHFR c.1298A>C AA AC CC χ2 P 
 
PCNSL (n = 185) 0.39 0.52 0.09 5.38 0.068 
 
Controls (n = 212) 0.50 0.42 0.08   
 
RFC c.80G>A GG GA AA χ2 P 
 
PCNSL (n = 185) 0.37 0.47 0.16 2.08 0.354 
 
Controls (n = 212)          0.36 0.43 0.21   
 
TYMS 28-bp repeat (2R>3R)  2R / 2R 2R / 3R 3R / 3R χ2 P 
 
PCNSL (n = 185) 0.22 0.50 0.28 0.666 0.717 
 
Controls (n = 212)               0.21 0.48 0.31   
 
MTR c.2756A>G AA AG GG χ2 P 
 
PCNSL (n = 185) 0.71 0.25 0.04 4.17 0.125 
 
Controls (n = 212)           0.62 0.34 0.04   
 
DHFR c.594+59del19-bp ins / ins ins / del del / del χ2 P 
 
PCNSL (n = 185) 0.33 0.45 0.22 1.27 0.53 
 
Controls (n = 212)              0.35 0.47 0.18   
 
CBS c.844_855ins68 del /del del / ins ins / ins χ2 P 
 
PCNSL (n = 185)  0.87 0.13         0.005 0.039 0.981 
 
Controls (n = 212)          0.87 0.12         0.005   
 
Tc2 c.776C>G CC CG GG χ2 P 
 
PCNSL (n = 185) 0.33 0.41 0.26 2.17 0.338 
 
Controls (n = 212)      0.27 0.47 0.26   
 
 
The rate of carriers of the different genotypes is given as relative amount. The Chi2 test values 
for Pearson`s Chi2 test for all three genotypes (= two degrees of freedom) for the differences 
between patients and controls are shown.  
 
